Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors.
about
SPECT and PET imaging of angiogenesis and arteriogenesis in pre-clinical models of myocardial ischemia and peripheral vascular diseaseDesign and preclinical evaluation of a 99mTc-labelled diabody of mAb J591 for SPECT imaging of prostate-specific membrane antigen (PSMA).Molecular imaging of angiogenesis with SPECT.Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy.89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.Evaluation of phage display discovered peptides as ligands for prostate-specific membrane antigen (PSMA).Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigenProdrugs for improving tumor targetability and efficiency.A targeted low molecular weight near-infrared fluorescent probe for prostate cancer.Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors.Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics.Functional prostate-specific membrane antigen is enriched in exosomes from prostate cancer cellsPharmacokinetic and Biodistribution Assessment of a Near Infrared-Labeled PSMA-Specific Small Molecule in Tumor-Bearing Mice.Targeting the prostate-specific membrane antigen for prostate cancer therapy.Clinical applications in molecular imaging.Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancerGeneral overview of radioimmunotherapy of solid tumors.Expression of prostate-specific membrane antigen in renal cortical tumors.In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe.The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological diseaseDevelopment and screening of a series of antibody-conjugated and silica-coated iron oxide nanoparticles for targeting the prostate-specific membrane antigen.⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy.Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers.High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity.Expression of Prostate-Specific Membrane Antigen (PSMA) in Brain Glioma and its Correlation with Tumor Grade.Emerging classes of armed antibody therapeutics against cancerIn Vivo 3T Magnetic Resonance Imaging Using a Biologically Specific Contrast Agent for Prostate Cancer: A Nude Mouse Model
P2860
Q28066121-04322FC3-796B-4419-AC67-0C95B70A7E99Q33586706-3DF986F0-F78A-47B5-8168-3B7C4CAE3C39Q34040149-664E5176-B37E-44EE-9D7F-FB8B0D84A926Q34241388-F66F5FF0-40F9-4EEC-8833-D7237FE73BA6Q34389457-CC194748-D61B-40AA-86CE-F56BCC6D395EQ34918072-67782234-C6B6-48F8-8F06-3EF88243C9E9Q35035214-B27ABD44-E426-47C4-9113-1B01BEFF97C2Q35095165-7D211541-A50E-4C11-8055-83018EF49B65Q35446801-79B8E602-FFA2-4ACC-9A98-0D5983924BD8Q35587920-727FA22E-A91A-490E-A8BE-7F32E87B8A3DQ37236103-1E3AEA01-79A2-414B-A6D1-533EDC764C10Q37591940-3D9D54BF-6A44-4432-B6A5-140D9DF51523Q37719087-0DF63F19-F9DD-43CC-B6A6-D7CA4EFCE599Q37773273-312A2DD2-F90D-4B65-8CC3-2AEE703A3850Q37815405-CFE62B17-9508-4519-8DE4-2FB069351EB9Q37972920-DE2A9954-91EB-41A8-AAAE-31C815982682Q38103579-8199744E-0EC7-4F6E-B8B4-A9F8E89E837CQ38427354-408E29F0-129A-4CDB-AC74-5F5671A20ABEQ38784721-7080FD14-ADC9-4933-AD22-B483D33F2843Q38831232-B28B412E-C249-420D-9158-4DAB2699381FQ39018873-47498AC1-9A5C-4A73-A38A-C3CFDBD4D294Q39828822-CB8D40EB-B282-4555-9A2B-B729B273744DQ40735810-86379872-185E-45BC-BAF9-A9E84E1DCFCEQ42140893-2370897F-02EE-4B98-B43D-0EBFAA04BC70Q44323544-151686A0-9814-422A-9AA4-44D04A3D9BB8Q53176736-9E85DEE8-6DEB-411A-90A3-EF069DEDFC5BQ55288869-2E268562-F75B-4FB9-86F2-2E77805DF9ECQ57911948-B7DF75DD-7F31-4D5B-9A0C-48FE956340B2Q59146880-AD119C02-A6F6-454B-9665-6B31685DBC26
P2860
Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors.
@en
type
label
Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors.
@en
prefLabel
Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors.
@en
P2093
P1476
Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors
@en
P2093
Angelo Nacca
Chaitanya R Divgi
Howard I Scher
Lawrence Schwartz
Neeta Pandit-Taskar
Peter Smith-Jones
Ronald Finn
Samantha Bender
Steven Larson
Susan Slovin
P304
P356
10.1158/1078-0432.CCR-06-2935
P407
P577
2007-05-01T00:00:00Z